Adamax is one of the few compounds in the research-peptide market where the label does not reliably tell you which molecule is in the vial. It is sold as an “upgraded Semax” — a nootropic peptide modified for greater stability and brain penetration — but two chemically different substances circulate under the single name “Adamax,” and no reference standard, PubChem record, or primary study exists to settle which one is authentic. This entry is a guide to what “Adamax” actually refers to, why the confusion exists, and what a researcher would need to do to know what they are holding.
Two molecules sold under one name
Both candidate structures start from the same backbone: Semax, the well-studied ACTH(4–10) analog (Met-Glu-His-Phe-Pro-Gly-Pro), N-terminally acetylated. Where they diverge is the C-terminus.
| Feature | Adamantane conjugate | Plain nonapeptide |
|---|---|---|
| Structure | Ac-Semax capped with an adamantane carboxamide | Ac-MEHFPGPAG-OH (nine residues, no adamantane) |
| Molecular formula | C50H69N11O11S | C44H61N11O13S |
| Molecular weight | ~1032.23 g/mol | ~984.10 g/mol |
| Adamantane present? | Yes — this is the whole point of the design | No — the formula cannot contain an adamantane cage |
| What it actually is | A peptide–small-molecule conjugate | An unremarkable acetylated peptide |
These are not two ways of writing the same thing. In the C44 formula, all 44 carbons are accounted for by the acetylated peptide itself, leaving none left over to build the rigid ten-carbon adamantane cage that defines the other structure. Independent recalculation of both molecular weights confirms each formula is internally consistent with its own structure — and that the two describe different compounds.
How the confusion started
The most likely origin is a notation error. Some catalogs write the sequence as “Ac-MEHFPGPAG,” and reading that trailing “AG” as alanine-glycine produces the plain nine-residue peptide. But “AG” almost certainly came from a different, real published compound: P21 (designated P021 in the same laboratory’s later work), a neurotrophic peptidergic compound, Ac-DGGLAG-NH2, in which the “AG” denotes an adamantylated glycine residue — not the two amino acids alanine and glycine (Li et al., FEBS Letters 2010; PMID 20600002). In other words, the “A” was originally shorthand for “adamantane,” and somewhere along the way it was transcribed as if it meant the amino acid alanine. Depending on how a given supplier’s synthesis house read the string, they may have made either molecule.
Why you cannot tell which one you have
The usual ways to pin down a compound’s identity all fail for Adamax:
- No PubChem record. A name search for “Adamax” returns nothing (HTTP 404). There is no authoritative structure to point to.
- The circulating CAS number is wrong. The CAS 114681-65-1 that at least one vendor assigns to Adamax actually belongs to RGD peptide (GRGDNP), an unrelated integrin-binding sequence. Citing it does not identify Adamax; it identifies a different molecule entirely.
- At least one published specification is arithmetically impossible. A widely copied “C22H52N16O6, MW 1032.24” computes to 636.76 g/mol, not 1032 — a sign the specs are being copied between listings without anyone checking them.
- Even the encyclopedic entry that exists cites no study. English Wikipedia lists the adamantane structure (C50H69N11O11S, 1032.23 g/mol) but references only a regulatory document, not a single primary paper — consistent with there being no research characterization to cite.
What the name is based on
The rationale behind “Adamax” is legitimate medicinal chemistry, even though it has never been tested in this specific molecule. Its parent, Semax, is cleared from plasma within minutes: degradation proceeds by removal of the terminal dipeptides, yielding shorter fragments (Zolotarev et al., Amino Acids 2006; PMID 16773243). N-terminal acetylation is a standard way to blunt that breakdown, and an adamantane cap is intended to add steric bulk against carboxypeptidases while sharply raising lipophilicity to favor blood-brain-barrier crossing. That adamantylation strategy is real and published — it produced the P21/P021 compound above, which has genuine support in aged-rat and Alzheimer’s-model research. Adamax appears to be an attempt to graft that strategy onto Semax. Whether the result keeps Semax’s activity, achieves the intended half-life, or crosses into the brain as designed has never been measured and published by anyone.
The evidence base
There is no primary literature on Adamax itself: no published synthesis, no analytical characterization, no pharmacokinetics, no receptor-binding data, no animal behavioral study, and no human trial. A PubMed search for “Adamax” returns only papers about “AdaMax,” an unrelated machine-learning algorithm. The supporting research that vendors invoke belongs to other molecules — Semax (over 200 PubMed-indexed records, though concentrated in one national research tradition and approved as a medicine only in Russia and Ukraine) and the P21/P021 adamantane peptide. Extrapolating from either to Adamax is an assumption, not evidence: attaching a bulky lipophilic cage to a short peptide can abolish target binding just as easily as it can improve delivery, and only direct measurement can tell the two outcomes apart. Vendor claims that Adamax is “two to three times more potent than Semax” or has a “longer half-life” trace to marketing copy, not to any published measurement.
Regulatory status
The most authoritative document naming Adamax anywhere is a regulatory one: in a June 2025 submission, New Zealand’s Medsafe identified Adamax among peptides encountered in border seizures and proposed classifying it as a prescription medicine. Adamax holds no FDA or EMA approval and is not an approved therapeutic in any major market. It is a research chemical, not a medicine.
This article is educational reference only. Adamax is a research compound with no established human use, no standardized dosing, and an unresolved chemical identity. Nothing here is medical advice.